Kinevac is a drug owned by Bracco Diagnostics Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 16, 2022. Details of Kinevac's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6803046 | Sincalide formulations |
Aug, 2022
(2 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Kinevac's patents.
Latest Legal Activities on Kinevac's Patents
Given below is the list of recent legal activities going on the following patents of Kinevac.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Request for Trial Denied Critical | 31 May, 2019 | US6803046 |
| Petition Requesting Trial | 19 Nov, 2018 | US6803046 |
| File Marked Found | 18 Jan, 2018 | US6803046 |
| File Marked Found | 13 Jun, 2017 | US6803046 |
| Change in Power of Attorney (May Include Associate POA) Critical | 21 Aug, 2007 | US6803046 |
| Correspondence Address Change Critical | 20 Aug, 2007 | US6803046 |
| Recordation of Patent Grant Mailed Critical | 12 Oct, 2004 | US6803046 |
| Patent Issue Date Used in PTA Calculation Critical | 12 Oct, 2004 | US6803046 |
| Issue Notification Mailed Critical | 23 Sep, 2004 | US6803046 |
| Receipt into Pubs | 31 Aug, 2004 | US6803046 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Kinevac and ongoing litigations to help you estimate the early arrival of Kinevac generic.
Kinevac's Litigations
Kinevac been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 19, 2018, against patent number US6803046. The petitioner Maia Pharmaceuticals, Inc., challenged the validity of this patent, with Bracco Diagnostics Inc. as the respondent. Click below to track the latest information on how companies are challenging Kinevac's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6803046 | November, 2018 |
Terminated-Denied
(31 May, 2019) | Bracco Diagnostics Inc. | Maia Pharmaceuticals, Inc. |
US patents provide insights into the exclusivity only within the United States, but Kinevac is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Kinevac's family patents as well as insights into ongoing legal events on those patents.
Kinevac's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Kinevac's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 16, 2022 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Kinevac Generics:
There are no approved generic versions for Kinevac as of now.
Alternative Brands for Kinevac
There are several other brand drugs using the same active ingredient (Sincalide) as Kinevac. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Maia Pharms Inc |
|
About Kinevac
Kinevac is a drug owned by Bracco Diagnostics Inc. Kinevac uses Sincalide as an active ingredient. Kinevac was launched by Bracco in 1982.
Approval Date:
Kinevac was approved by FDA for market use on 01 January, 1982.
Active Ingredient:
Kinevac uses Sincalide as the active ingredient. Check out other Drugs and Companies using Sincalide ingredient
Dosage:
Kinevac is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.005MG/VIAL | POWDER | Prescription | INTRAVENOUS |